CU24400B1 - Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas - Google Patents

Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas

Info

Publication number
CU24400B1
CU24400B1 CU2015000140A CU20150140A CU24400B1 CU 24400 B1 CU24400 B1 CU 24400B1 CU 2015000140 A CU2015000140 A CU 2015000140A CU 20150140 A CU20150140 A CU 20150140A CU 24400 B1 CU24400 B1 CU 24400B1
Authority
CU
Cuba
Prior art keywords
dihydroimidazo
composition
inhibitor
kinazolins
substituted
Prior art date
Application number
CU2015000140A
Other languages
English (en)
Other versions
CU20150140A7 (es
Inventor
Katja Haike
Dr Ningshu Liu
Juliane Paul
Dr Antje Margret Wengner
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CU20150140A7 publication Critical patent/CU20150140A7/es
Publication of CU24400B1 publication Critical patent/CU24400B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

<p>La presente invención está relacionada  con una composición, que comprende una combinación de: a) un compuesto del tipo 2,3-dihidroimidazo [1,2-c]quinazolinas de fórmula general:</p> <p>ESPACIO PARA FÓRMULA</p> <p>, o composiciones farmacéuticas que lo contienen, como único agente activo, y b) un agente activo adicional que se selecciona del grupo que consiste en el inhibidor selectivo de la PI3K DELTA GS-1101, el inhibidor de las BTK ibrutinib, el compuesto inhibidor de las IKK BAY B y el refametinib (BAY 86-9766, RDEA-119).</p>
CU2015000140A 2013-04-08 2014-04-04 Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas CU24400B1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13162710 2013-04-08
EP13184240 2013-09-13
PCT/EP2014/056768 WO2014166820A1 (en) 2013-04-08 2014-04-04 Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for treating lymphomas

Publications (2)

Publication Number Publication Date
CU20150140A7 CU20150140A7 (es) 2016-10-28
CU24400B1 true CU24400B1 (es) 2019-04-04

Family

ID=50439383

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2015000140A CU24400B1 (es) 2013-04-08 2014-04-04 Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituidas

Country Status (27)

Country Link
US (2) US9999623B2 (es)
EP (1) EP2983669B1 (es)
JP (1) JP6368353B2 (es)
KR (1) KR102304108B1 (es)
CN (1) CN105263497B (es)
AP (1) AP2015008750A0 (es)
AU (1) AU2014253348B2 (es)
BR (1) BR112015025304B1 (es)
CA (1) CA2908776C (es)
CL (1) CL2015002978A1 (es)
CR (1) CR20150523A (es)
CU (1) CU24400B1 (es)
DO (1) DOP2015000256A (es)
EA (2) EA037577B1 (es)
ES (1) ES2708350T3 (es)
IL (1) IL241543B (es)
JO (1) JOP20140141B1 (es)
MX (1) MX2015014171A (es)
MY (1) MY192626A (es)
NI (1) NI201500148A (es)
PE (1) PE20151780A1 (es)
PH (1) PH12015502317A1 (es)
SG (2) SG11201507265XA (es)
TN (1) TN2015000452A1 (es)
TW (2) TWI675663B (es)
UA (2) UA119537C2 (es)
WO (1) WO2014166820A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
EP2508525A1 (en) * 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
US10124007B2 (en) 2013-12-03 2018-11-13 Bayer Pharma Aktiengesellschaft Combination of PI3K-inhibitors
WO2015082376A2 (en) * 2013-12-03 2015-06-11 Bayer Pharma Aktiengesellschaft Use of pi3k-inhibitors
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
WO2016087490A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
WO2016087488A1 (en) * 2014-12-03 2016-06-09 Bayer Pharma Aktiengesellschaft Administration regime for aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations
US9717745B2 (en) 2015-03-19 2017-08-01 Zhejiang DTRM Biopharma Co. Ltd. Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases
RU2018103913A (ru) 2015-07-02 2019-08-02 Асерта Фарма Б.В. Твердые формы и композиции (s)-4-(8-амино-3-(1-(бут-2- иноил)пирролидин-2-ил)имидазо[1,5-a]пиразин-1-ил)-n-(пиридин-2-ил)бензамида
CA3012951A1 (en) * 2016-02-01 2017-08-10 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
EP3411497A1 (en) * 2016-02-01 2018-12-12 Bayer Pharma Aktiengesellschaft Copanlisib biomarkers
CA3016584A1 (en) 2016-03-08 2017-09-14 Bayer Pharma Aktiengesellschaft 2-amino-n-[7-methoxy-2,3-dihydroimidazo-[1,2-c]quinazolin-5-yl]pyrimidine-5-carboxamides
EP3219329A1 (en) * 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2017221092A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Triazolopyridine compounds and uses thereof
US10676479B2 (en) * 2016-06-20 2020-06-09 Novartis Ag Imidazolepyridine compounds and uses thereof
CA3037626A1 (en) * 2016-09-23 2018-03-29 Bayer Pharma Aktiengesellschaft Combination of pi3k-inhibitors
TWI810185B (zh) * 2017-05-18 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 一種ｅｚｈ２抑制劑與ｂｔｋ抑制劑聯合在製備治療腫瘤的藥物中的用途
EP3645005A1 (en) 2017-06-28 2020-05-06 Bayer Consumer Care AG Combination of a pi3k-inhibitor with an androgen receptor antagonist
SG11202002356XA (en) * 2017-09-13 2020-04-29 Guangdong Oppo Mobile Telecommunications Corp Ltd Data processing method, terminal device and network device
TW201922256A (zh) 2017-10-27 2019-06-16 中國大陸商浙江導明醫藥科技有限公司 治療淋巴樣惡性疾病之方法
US20230029385A1 (en) * 2019-10-15 2023-01-26 Bayer Aktiengesellschaft 2-methyl-aza-quinazolines
CN115120596A (zh) * 2021-03-26 2022-09-30 上海璎黎药业有限公司 一种喹唑啉化合物及药物组合物的应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1400959A (en) 1919-04-26 1921-12-20 Ste Chim Usines Rhone Process and apparatus for carrying out chemical reactions by catalysis
US1364099A (en) 1919-09-10 1921-01-04 Flannery Bolt Co Staybolt structure for boilers
US1400975A (en) 1920-10-11 1921-12-20 Page Henry Benjiman Dirigible headlight for motor-vehicles
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
JP2003277383A (ja) 2002-03-14 2003-10-02 Bayer Ag 光学活性ピリジン誘導体およびそれを含む医薬
AU2003293310B2 (en) 2002-09-30 2010-04-01 Bayer Intellectual Property Gmbh Fused azole-pyrimidine derivatives
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
JP5620275B2 (ja) 2008-01-14 2014-11-05 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 超増殖性疾患及び脈管形成に関連する疾病を処理するために有用なスルホン置換された２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン誘導体類
EP2168583A1 (en) 2008-09-24 2010-03-31 Bayer Schering Pharma Aktiengesellschaft Use of substituted 2,3-dihydroimidazo[1,2-c]quinazolines for the treatment of myeloma
PE20130191A1 (es) 2010-04-16 2013-02-21 Bayer Ip Gmbh Combinaciones que contienen 2, 3-dihidroimidazo[1, 2-c]quinazolina sustituida
CN102893688B (zh) 2010-05-14 2016-03-09 Lg电子株式会社 在无线通信系统中分配资源的方法及其装置
UA113280C2 (xx) 2010-11-11 2017-01-10 АМІНОСПИРТЗАМІЩЕНІ ПОХІДНІ 2,3-ДИГІДРОІМІДАЗО$1,2-c]ХІНАЗОЛІНУ, ПРИДАТНІ ДЛЯ ЛІКУВАННЯ ГІПЕРПРОЛІФЕРАТИВНИХ ПОРУШЕНЬ І ЗАХВОРЮВАНЬ, ПОВ'ЯЗАНИХ З АНГІОГЕНЕЗОМ
JP5790016B2 (ja) 2011-02-18 2015-10-07 コベルコ建機株式会社 ハイブリッド建設機械
RU2568258C2 (ru) * 2011-02-28 2015-11-20 Саншайн Лейк Фарма Ко., Лтд Замещенные соединения хинолина и способы их использования
US20140213630A1 (en) * 2011-03-08 2014-07-31 Thomas Diacovo Methods and pharmaceutical compositions for treating lymphoid malignancy
EP2508525A1 (en) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts
JO3733B1 (ar) 2011-04-05 2021-01-31 Bayer Ip Gmbh استخدام 3,2-دايهيدروايميدازو[1, 2 -c]كوينازولينات مستبدلة
ES2624981T3 (es) * 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
WO2013169858A1 (en) * 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US8993891B2 (en) 2012-06-28 2015-03-31 Thomas & Betts International, Inc. Lift and pivot grommet
JP6499657B2 (ja) 2013-12-03 2019-04-10 バイエル ファーマ アクチエンゲゼルシャフト Ｐｉ３ｋ阻害剤の組み合わせ
EP3018131A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
EP3018127A1 (en) 2014-11-07 2016-05-11 Bayer Pharma Aktiengesellschaft Synthesis of copanlisib and its dihydrochloride salt
JP2018512403A (ja) 2015-03-09 2018-05-17 バイエル ファーマ アクチエンゲゼルシャフト 置換２，３−ジヒドロイミダゾ［１，２−ｃ］キナゾリン類の使用
CA2978830A1 (en) 2015-03-09 2016-09-15 Bayer Pharma Aktiengesellschaft Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations

Also Published As

Publication number Publication date
JP2016515601A (ja) 2016-05-30
CA2908776C (en) 2021-08-10
TWI689307B (zh) 2020-04-01
EA031493B1 (ru) 2019-01-31
DOP2015000256A (es) 2015-12-31
CN105263497A (zh) 2016-01-20
EA201792650A1 (ru) 2018-04-30
ES2708350T3 (es) 2019-04-09
TN2015000452A1 (en) 2017-04-06
CR20150523A (es) 2016-01-29
KR20150138858A (ko) 2015-12-10
SG11201507265XA (en) 2015-10-29
TWI675663B (zh) 2019-11-01
AP2015008750A0 (en) 2015-09-30
TW201924690A (zh) 2019-07-01
SG10201710539QA (en) 2018-01-30
JOP20140141B1 (ar) 2021-08-17
EP2983669B1 (en) 2018-10-24
JP6368353B2 (ja) 2018-08-01
HK1220121A1 (zh) 2017-04-28
CU20150140A7 (es) 2016-10-28
UA122822C2 (uk) 2021-01-06
US20160058770A1 (en) 2016-03-03
CL2015002978A1 (es) 2016-04-15
UA119537C2 (uk) 2019-07-10
US9999623B2 (en) 2018-06-19
TW201517909A (zh) 2015-05-16
EA037577B1 (ru) 2021-04-16
US10226469B2 (en) 2019-03-12
US20180193349A1 (en) 2018-07-12
AU2014253348B2 (en) 2019-05-23
KR102304108B1 (ko) 2021-09-23
WO2014166820A1 (en) 2014-10-16
NZ712033A (en) 2021-03-26
EA031493B9 (ru) 2019-12-18
EA201591932A1 (ru) 2016-04-29
MX2015014171A (es) 2015-12-16
MY192626A (en) 2022-08-29
EP2983669A1 (en) 2016-02-17
AU2014253348A1 (en) 2015-10-08
PH12015502317A1 (en) 2016-02-10
BR112015025304A2 (pt) 2017-07-18
PE20151780A1 (es) 2015-12-20
CN105263497B (zh) 2019-04-30
BR112015025304B1 (pt) 2022-09-27
IL241543B (en) 2019-08-29
NI201500148A (es) 2015-11-30
CA2908776A1 (en) 2014-10-16

Similar Documents

Publication Publication Date Title
CU20150140A7 (es) Una composición que comprende 2,3-dihidroimidazo[1,2-c]quinazolinas sustituídas
MX2018015709A (es) Derivados de azabencimidazol como inhibidores de pi3k beta.
CL2018001031A1 (es) Inhibidores de ferroportina novedosos
NI201700135A (es) Derivados de ciclohexano sustituido con amido
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
MX2018002326A (es) Analogos novedosos de nucleosidos sustituidos en el anillo aromatico biciclico 6-6 para su uso como inhibidores de prmt5.
DOP2016000085A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
UY35237A (es) Composiciones que comprenden un compuesto de triazol
UY35238A (es) Composiciones que comprenden un compuesto de triazol
PE20151423A1 (es) Derivados tetrahidropiranilo inhibidores del hcv
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CR20150175A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
MX2018004304A (es) DERIVADOS DE QUINOXALINA Y PIRIDOPRAZINA COMO INHIBIDORES DE PI3Kß.
DOP2015000170A (es) Compuestos químicos
DOP2016000007A (es) Pirazolpiridinas sustituidas
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
CU20160072A7 (es) Tienopirimidinas como inhibidores mknk1 y mknk2
UY35332A (es) Derivados de pirrolotriazina como inhibidores de pi3k
PH12016501932A1 (en) Amido-substituted azole compounds
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
CO2019003761A2 (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos
MX2018015707A (es) Derivados biciclicos de piridina, pirazina y pirimidina como inhibidores de pi3k beta.
MX2019011610A (es) Derivados de quinoxalina y piridoprazina como inhibidores de pi3k-beta.